← Product Code [GEX](/submissions/SU/subpart-e%E2%80%94surgical-devices/GEX) · K963969 # INDIGO PORTABLE LASER SYSTEM WITH TEMPERATURE FEEDBACK -MODEL IDL 830 (POWER OPTIONS : 25, 20, 15 & 10 WATTS) INDIGO FIB (K963969) _Indigo Medical, Inc. · GEX · Dec 23, 1997 · General, Plastic Surgery · SESE_ **Canonical URL:** https://fda.innolitics.com/submissions/SU/subpart-e%E2%80%94surgical-devices/GEX/K963969 ## Device Facts - **Applicant:** Indigo Medical, Inc. - **Product Code:** [GEX](/submissions/SU/subpart-e%E2%80%94surgical-devices/GEX.md) - **Decision Date:** Dec 23, 1997 - **Decision:** SESE - **Submission Type:** Traditional - **Regulation:** 21 CFR 878.4810 - **Device Class:** Class 2 - **Review Panel:** General, Plastic Surgery - **Attributes:** Therapeutic ## Intended Use The Indigo 830e LaserOptic Treatment System with Diffuser-Tip™ Fiberoptic is indicated for the treatment of symptoms due to urinary outflow obstruction secondary to benign prostatic hyperplasia (BPH) in men over the age of 50 with prostates with median and/or lateral lobes ranging in total volume from 20-85 cc and for general surgery, general urological and gastroenterological procedures including the incision, excision, and ablation of soft tissues; and coagulative necrosis and interstitial laser coagulation of soft tissues. ## Device Story Indigo 830e LaserOptic Treatment System uses diode laser energy delivered via Diffuser-Tip™ fiberoptics to perform interstitial laser coagulation (ILC) and general surgical procedures. Device elevates tissue temperature to 60-100°C to induce necrosis without carbonization. Used by physicians in clinical/surgical settings for BPH treatment and soft tissue management. System provides power for cutting or coagulating tissues; lesion size controlled by diffuser length and tissue conditions. Benefits include minimally invasive treatment of BPH symptoms and precise soft tissue ablation. ## Clinical Evidence Prospective, randomized study conducted to evaluate safety and effectiveness for BPH treatment. Bench testing included in vitro porcine tissue studies measuring penetration depth (mm) across various power (5-25W) and time (1-5s) settings in liver, kidney, and heart tissues. ## Technological Characteristics Diode laser system; Diffuser-Tip™ fiberoptic delivery; interstitial laser coagulation principle; operates by thermal necrosis (60-100°C). ## Regulatory Identification (1) A carbon dioxide laser for use in general surgery and in dermatology is a laser device intended to cut, destroy, or remove tissue by light energy emitted by carbon dioxide.(2) An argon laser for use in dermatology is a laser device intended to destroy or coagulate tissue by light energy emitted by argon. ## Predicate Devices - [K955798](/device/K955798.md) ## Submission Summary (Full Text) > This content was OCRed from public FDA records by [Innolitics](https://innolitics.com). If you use, quote, summarize, crawl, or train on this content, cite Innolitics at https://innolitics.com. > > Innolitics is a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices, including [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/). {0} K963969 # Section K : Summary of Safety and Effectiveness DEC 23 1997 Invitro and human clinical testing were conducted to establish the equivalence to predicate devices in terms of safety and efficacy and to characterize the performance of the laser system with different types of fiber optics. When used as a general surgical instrument, the laser is able to provide power to cut or coagulate tissues. The table below shows the penetration depth in porcine tissues (invitro) as a function of time and exposure to diode laser power. | Exposure Power/Time | Penetration Depth (mm) | | | | --- | --- | --- | --- | | | Liver | Kidney | Heart | | 5 Watts / 1 sec | 1.73±0.20 | 1.75±0.34 | 1.77±0.37 | | 5 Watts / 2 sec | 2.48±0.73 | 2.29±0.31 | 2.19±0.62 | | 5 Watts / 5 sec | 3.37±0.64 | 3.31±0.39 | 3.03±0.72 | | 10 Watts / 1 sec | 2.26±0.47 | 1.90±0.35 | 2.25±0.62 | | 10 Watts / 2 sec | 3.30±0.59 | 2.36±0.27 | 2.16±0.35 | | 10 Watts / 5 sec | 4.34±0.78 | 3.65±0.54 | 2.89±0.34 | | 15 Watts / 1 sec | 2.35±0.45 | 2.60±0.35 | 2.16±0.32 | | 15 Watts / 2 sec | 3.61±0.50 | 3.17±0.38 | 2.58±0.34 | | 20 Watts / 1 sec | 2.99±0.48 | 2.64±0.50 | 1.99±0.36 | | 20 Watts / 2 sec | 3.27±1.34 | 2.98±0.77 | 3.48±0.79 | | 25 Watts / 1 sec | 2.81±1.13 | 2.24±0.53 | 2.96±0.83 | | 25 Watts / 2 sec | 3.65±0.72 | 3.17±1.04 | 2.81±0.44 | When used as a coagulating device, the Índigo laser in conjunction with a diffusing fiberoptic provides interstitial laser coagulation. The process of interstitial laser coagulation relies on quickly elevating tissue to a temperature range (Approx. 60 to 100°C) where tissue necrosis rapidly occurs, but below temperatures at which carbonization begins. Lesion sizes vary according to diffuser length and variation of tissue conditions. The results of a prospective, randomized study shows that the Índigo procedure is safe and effective for the treatment of Benign Prostate Hyperplasia. {1} DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850 Ms. Sharon Starowicz Director of Regulatory, Clinical and Quality Systems Indigo Medical, Incorporated 10123 Alliance Road Cincinnati, Ohio 45242 DEC 23 1997 Re: K963969 Trade Name: Indigo 830e LaserOptic Treatment System with Diffuser-Tip™ Fiberoptic Regulatory Class: II Product Code: GEX Dated: September 29, 1997 Received: September 30, 1997 Dear Ms. Starowicz: We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic (QS) inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for {2} Page 2 - Ms. Starowicz devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations. This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market. If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for *in vitro* diagnostic devices), please contact the Office of Compliance at (301) 594-4595. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "http://www.fda.gov/cdrh/dsmamain.html". Sincerely yours, ![img-0.jpeg](img-0.jpeg) Celia M. Witten, Ph.D., M.D. Director Division of General and Restorative Devices Office of Device Evaluation Center for Devices and Radiological Health Enclosure {3} # INDICATIONS FOR USE 510(k) Number: K963969 Device Name: Indigo 830e LaserOptic Treatment System with Diffuser-Tip™ Fiberoptic Indications for Use: Note: Indigo is requesting the expansion of the indications for use which have already been cleared under K955798 for general surgery, general urological and gastroenterological procedures including the incision, excision, and ablation of soft tissues; and coagulative necrosis and interstitial laser coagulation of soft tissues. The expanded Indications for Use will read as follows: The Indigo 830e LaserOptic Treatment System with Diffuser-Tip™ Fiberoptic is indicated for the treatment of symptoms due to urinary outflow obstruction secondary to benign prostatic hyperplasia (BPH) in men over the age of 50 with prostates with median and/or lateral lobes ranging in total volume from 20-85 cc and for general surgery, general urological and gastroenterological procedures including the incision, excision, and ablation of soft tissues; and coagulative necrosis and interstitial laser coagulation of soft tissues. Concurrence of CDRH, Office of Device Evaluation (ODE) (Division Sign-OS) Division of General Restorative Devices 510(k) Number K 96 3969 Prescription Use ☑ OR Over-the-Counter Use (Per 21 CFR 801.109) (Optional Format 1-2-96) 00011 --- **Source:** [https://fda.innolitics.com/submissions/SU/subpart-e%E2%80%94surgical-devices/GEX/K963969](https://fda.innolitics.com/submissions/SU/subpart-e%E2%80%94surgical-devices/GEX/K963969) **Published by [Innolitics](https://innolitics.com)** — a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices. If you're preparing [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/), [get in touch](https://innolitics.com/contact). **Cite:** Innolitics at https://innolitics.com